Leadership

GBI’s senior operational staff members have decades of experience in biologics and cGMP manufacturing, including holding senior positions at numerous leading biopharmaceutical companies.

Darrin T. Schellin Chief Executive Officer

Sunil Agarwal Financial Controller

Muctarr Sesay; Chief Science Officer, Vice President, Bioconjugation Development at GBI

Muctarr Sesay, Ph.D. Chief Science Officer, Vice President, Bioconjugation Development

Kenneth Meek; Vice President of Business Operations at GBI

Kenneth Meek Vice President, Business Operations

Amita Quadros, Associate Vice President / Client Services at GBI

Amita Quadros, Ph.D. Associate Vice President, Client Services

Andrew Majdoch, Associate Vice President, Technical Operations at GBI

Andrew Majdoch, MSc Associate Vice President, Technical Operations

Prema Rathinavelu, Associate Vice President, Quality Control at GBI

Prema Rathinavelu, MSc Associate Vice President, Quality Control

Darrin T. Schellin Chief Executive Officer

Darrin is a very experienced senior executive with a distinguished career spanning several decades internationally in the life sciences and CDMO industries at organizations including Bausch & Lomb, Alliance Medical Products, and Siegfried Holding AG among others. Darrin was integral to the leadership team at Alliance Medical Products as COO and then CEO, growing the company rapidly over a decade until it was sold to Swiss CDMO Siegfried Holding AG. Darrin then ran Siegfried’s global drug products business for six years, managing five sites across the US and Europe. He has strong leadership skills and experience and is passionate about building organizations and integrating complex service offerings and technologies with business operations to ensure efficiencies, scalability, and a high degree of customer satisfaction.

Sunil Agarwal Financial Controller

Sunil Agarwal is a Certified Public Accountant (CPA) and Internal Auditor (CIA) working as the Financial Controller at GBI.

Sunil joined GBI in 2009 with broad experience in the manufacturing and service industries. He has handled the finance and auditing responsibilities for companies including Universal Healthcare Services, Layered Technology, Transcorp International Ltd, and various public accounting firms.

In his current role, Sunil focuses on the finance and accounting functions within the company and also takes care of related commercial and statutory responsibilities. A key part of the management team, Sunil’s strengths in decision-making, his industry knowledge, and his extensive working experience with American and Indian GAAP make him a strong contributor to the company’s success.

Muctarr Sesay, Ph.D. Chief Science Officer, Vice President, Bioconjugation Development

Dr. Sesay has over 25 years of biotechnology experience in biologics process development and manufacturing, bioconjugation and modification of biological molecules (including monoclonal and polyclonal antibodies, enzymes, toxins, and others) and small molecules. He also has over 17 years of experience in the Contract Development and Manufacturing (CDMO) sectors. Prior to joining GBI in 2002, Dr. Sesay supervised many projects in R&D, process development, and biologics manufacturing at Life Technologies Inc. (now Thermo Fischer), Kirkegaard and Perry Laboratories (KPL), and Elusys Therapeutics. After receiving his Ph.D. in Biochemistry from the University of London (Queen Mary College), England, Dr. Sesay worked for three years as a postdoctoral candidate at the University of Maryland, College Park in protein purification and characterization. In addition to his responsibilities at GBI, Dr. Sesay is also a member of the advisory committee for the Professional Science Master’s Degree in Medical Biotechnology offered by the College of Health Sciences at Barry University.

Kenneth Meek Vice President, Business Operations

Mr. Meek received his BS in chemical engineering from North Carolina State University with a concentration in biochemistry. He has over 15 years of experience in business development and marketing for preclinical research proof-of-concept services including in vivo and in vitro efficacy models to stable cell line development. He has forged collaborations with global cGMP service providers and CMC consultants, facilitating many new molecules that have resulted in positive clinical outcomes and significant financial milestones. He led business development and marketing for Aragen Bioscience, resulting in the eventual acquisition by GVK Bio, one of Asia’s largest Contract Research Organizations. Mr. Meek also launched the global sales and marketing initiative for MabPlex International, Ltd., resulting in MabPlex’s first major end-to-end GMP campaign outside of China.

Amita Quadros, Ph.D. Associate Vice President, Client Services

Dr. Quadros is well-versed as a client advocate at GBI, having worked for over 15 years in pre-clinical research and phase I-III/BE clinical trials in a variety of therapeutic indications such as Alzheimer’s disease, cancer, cardiovascular disease, hypertension, and diabetes. Her attention to detail and management skills were honed by supervising over 30 employees, and she has authored and co-authored over 20 peer-reviewed articles and presented her work at international conferences via various poster and platform presentations. Dr. Quadros was also the lead author in a chapter of a seminal text in COX-2 inhibitor research and is an editor and reviewer for Scientific Journals International (SJI). In addition to her full-time position as Project Manager at GBI, Dr. Quadros contributes her scientific knowledge as a Professor of Biology at Broward College. She completed her undergraduate work in biochemistry at the University of Bombay and received her Ph.D. at Florida International University.

Andrew Majdoch, MSc Associate Vice President, Technical Operations

Andrew has over 20 years of experience in manufacturing biologics and biopharmaceuticals. Prior to joining GBI, Andrew was the Senior Manager – Clinical Manufacturing and Process Development at Alkermes plc, where he worked for 13 years in manufacturing (commercial and clinical) and process development. Andrew has experience developing drug candidates in the large molecule design space focusing on recombinant therapeutic proteins. Andrew began his career with Abbott Laboratories where he worked for 7 years moving up through the ranks to become the Rare Reagents Manufacturing Supervisor overseeing the mAb production suite. At GBI, Andrew is responsible for all manufacturing operations including GMP and non-GMP upstream, downstream, and fill finish as well as associated support activities such as materials management and facilities. Andrew earned his Masters of Science degree in engineering and technology management from Oklahoma State University and a Bachelor of Science degree in biology from the University of Wisconsin.

Prema Rathinavelu, MSc Associate Vice President, Quality Control

With over 17 years of experience in managing quality assurance and quality control departments, Prema has leveraged a solid scientific background with technical experience in biochemistry, microbiology, and chemistry, working on all aspects of early-stage drug development including analytical method development and validation as well as establishing product specifications. She has a deep understanding of USP and EP methodologies, which enables her to provide guidance and oversight for the release and testing of API, finished products, and raw materials. Prema attended the University of Madras, where she earned a Master’s degree in biochemistry and an undergraduate degree in chemistry, and has published several research papers in reputable, peer-reviewed biological journals.

Learn More

Board of Directors

Awards

Collaborations & Partnerships

Contact Us About Your CDMO Project

Learn More